Capitolis Liquid Global Markets LLC Invests $40.40 Million in Gilead Sciences, Inc. $GILD

Capitolis Liquid Global Markets LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 364,000 shares of the biopharmaceutical company’s stock, valued at approximately $40,404,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after buying an additional 1,893,401 shares during the last quarter. Norges Bank bought a new stake in Gilead Sciences in the second quarter valued at $2,150,268,000. Invesco Ltd. boosted its holdings in shares of Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after acquiring an additional 1,618,453 shares during the period. Amundi boosted its holdings in shares of Gilead Sciences by 18.2% during the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after acquiring an additional 1,614,355 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Gilead Sciences by 4.2% during the third quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock worth $1,133,376,000 after acquiring an additional 414,454 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. BMO Capital Markets upped their target price on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, January 26th. Scotiabank lifted their price target on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 11th. Finally, Wells Fargo & Company boosted their price objective on Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $157.62.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the completion of the transaction, the chief executive officer owned 642,308 shares in the company, valued at approximately $92,999,775.32. This trade represents a 1.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the transaction, the chief financial officer directly owned 167,779 shares in the company, valued at $25,910,110.97. This represents a 1.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 309,280 shares of company stock valued at $43,935,470 over the last 90 days. Insiders own 0.27% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analyst optimism — Jefferies and other firms have initiated or reiterated positive coverage, highlighting Gilead’s strong HIV franchise, expanding oncology/cell therapy pipeline and long IP runway (through ~2036), which supports both income and growth narratives. How Renewed Wall Street Optimism Around HIV, Oncology And IP Runway At Gilead Sciences (GILD) Has Changed Its Investment Story
• Positive Sentiment: Zacks raised near-term EPS estimates (Q1/Q2 and FY2027 upgrades reported), nudging earnings expectations higher — a constructive signal for investors focused on fundamentals. The Zacks Analyst Blog: Oracle, T?Mobile, Gilead and C&F Financial
• Positive Sentiment: Unusually large call-option activity (130k+ calls) signals bullish positioning by traders, which can amplify upside if catalysts continue. (Market data)
• Positive Sentiment: Index and institutional flows — rising institutional focus amid Nasdaq?100 dynamics can support demand for GILD shares from passive and quant funds. Gilead (NASDAQ:GILD) Institutional Focus Rises In Nasdaq 100 Index
• Neutral Sentiment: Acquisition rationale — coverage and analyst pieces discuss whether the ~$7.8B Arcellx buy strengthens Gilead’s cell?therapy franchise amid declining cell therapy sales; the strategic case is positive but clinical/commercial risks remain. Will GILD’s Move to Acquire ACLX Boost Its Cell Therapy Franchise?
• Neutral Sentiment: Market context — broader investor flows into growth/tech vs. traditional defensives are affecting healthcare sector moves; this macro backdrop is neither uniquely positive nor negative for Gilead. Why Investors Aren’t Fleeing to Safe?Haven Stocks
• Negative Sentiment: Deal/legal risk — a law firm (Kahn Swick & Foti) is investigating Arcellx’s proposed sale to Gilead, citing concerns over price/process; shareholder litigation or regulatory scrutiny could delay or alter the transaction terms and is a near?term overhang. Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc.

Gilead Sciences Stock Down 0.2%

Shares of GILD stock opened at $144.99 on Friday. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The business’s fifty day moving average is $140.62 and its 200-day moving average is $126.87. The stock has a market cap of $179.99 billion, a PE ratio of 21.42, a price-to-earnings-growth ratio of 1.90 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the firm posted $1.90 earnings per share. The company’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is currently 46.68%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.